- Home
- VIGL vs MGNX Comparison
VIGL vs MGNX Comparison
Compare VIGL & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- MGNX
- Stock Information
- Founded
- VIGL 2020
- MGNX 2000
- Country
- VIGL United States
- MGNX United States
- Employees
- VIGL N/A
- MGNX N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- VIGL Health Care
- MGNX Health Care
- Exchange
- VIGL Nasdaq
- MGNX Nasdaq
- Market Cap
- VIGL 74.7M
- MGNX 70.3M
- IPO Year
- VIGL 2022
- MGNX 2013
- Fundamental
- Price
- VIGL $1.81
- MGNX $1.69
- Analyst Decision
- VIGL Strong Buy
- MGNX Hold
- Analyst Count
- VIGL 5
- MGNX 10
- Target Price
- VIGL $16.33
- MGNX $6.83
- AVG Volume (30 Days)
- VIGL 141.7K
- MGNX 1.1M
- Earning Date
- VIGL 05-06-2025
- MGNX 05-08-2025
- Dividend Yield
- VIGL N/A
- MGNX N/A
- EPS Growth
- VIGL N/A
- MGNX N/A
- EPS
- VIGL N/A
- MGNX N/A
- Revenue
- VIGL N/A
- MGNX $149,962,000.00
- Revenue This Year
- VIGL N/A
- MGNX N/A
- Revenue Next Year
- VIGL N/A
- MGNX $80.86
- P/E Ratio
- VIGL N/A
- MGNX N/A
- Revenue Growth
- VIGL N/A
- MGNX 155.26
- 52 Week Low
- VIGL $1.31
- MGNX $0.99
- 52 Week High
- VIGL $6.06
- MGNX $16.59
- Technical
- Relative Strength Index (RSI)
- VIGL 53.10
- MGNX 54.78
- Support Level
- VIGL $1.31
- MGNX $1.10
- Resistance Level
- VIGL $1.66
- MGNX $1.34
- Average True Range (ATR)
- VIGL 0.16
- MGNX 0.15
- MACD
- VIGL 0.06
- MGNX 0.09
- Stochastic Oscillator
- VIGL 97.24
- MGNX 95.59
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.